Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback